Mineishi, S., Magenau, J., Pawarode, A., Buck, T., Jones, D., Kato, K., … Levine, J. E. (2008). Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML. In BLOOD (Vol. 112, pp. 749–749). San Francisco, CA: AMER SOC HEMATOLOGY.

Mineishi, Shin, John Magenau, Attaphol Pawarode, Timothy Buck, Dawn Jones, Koji Kato, David Frame, et al. “Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.” In BLOOD, 112:749–749. AMER SOC HEMATOLOGY, 2008.

Mineishi S, Magenau J, Pawarode A, Buck T, Jones D, Kato K, et al. Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML. In: BLOOD. AMER SOC HEMATOLOGY; 2008. p. 749–749.

Mineishi, Shin, et al. “Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, 2008, pp. 749–749.

Mineishi S, Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba HP, Khaled Y, Peres EM, Krijanovski OI, Reddy P, Kitko C, Choi S, Yanik GA, Braun T, Ferrara JLM, Levine JE. Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML. BLOOD. AMER SOC HEMATOLOGY; 2008. p. 749–749.